BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

07/25/2025

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) announces two clinical data poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany. Find details: https://bit.ly/4o56Fbp

07/23/2025

“We are thrilled to see our Bria-IMT regimen outperform established benchmarks like Trodelvy in TNBC and HR+ MBC patients,” stated Dr. William V. Williams, BriaCell’s President and CEO. Find BriaCell's updated Phase 2 survival data, here: https://bit.ly/44q98pd

07/21/2025

BriaCell President and CEO Dr. William V. Williams comments on the complete resolution of lung metastasis observed in the first patient treated with BriaCell's Bria-OTS Phase 1/2a study. Learn more: https://bit.ly/4nECbwA

07/17/2025

In a Phase 2 clinical study of 54 patients, Bria-IMT combination regimen produced robust (~2X longer) overall survival in patients versus competitor drugs.

BriaCell is enrolling patients in its ongoing clinical trial. If you or someone you love is facing , you may be eligible for this novel immunotherapy approach.

To determine eligibility, please visit: https://bit.ly/3WRwy2M

Survival benefit was observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhi...
07/16/2025

Survival benefit was observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhibitors (CPIs) and antibody-drug conjugates (ADCs). Learn more: https://bit.ly/3Ggl83o

07/15/2025

"We are very excited to be working with renowned clinical experts at a leading cancer center like Mayo Clinic, who also participated in BriaCell's Phase 2 study,” comments Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. To learn more about BriaCell's pivotal Phase 3 study, please visit: https://bit.ly/46GYCev

07/15/2025

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) announced the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study in metastatic breast cancer. BriaCell’s Phase 3 study now has 59 active clinical sites across 15 states. Find additional details: https://bit.ly/46GYCev

07/14/2025

"BriaCell’s survival data in single arm Phase 2 trial highlights the potential activity of Bria-IMT in combination with CPIs and is subject to ongoing investigation in a Phase 3 randomized clinical trial in MBC,"" said Aditya Bardia, MD, MPH, FASCO, a leading breast cancer expert. Learn more about BriaCells Phase 2 survival achievement: https://bit.ly/3Ggl83o

07/14/2025

BriaCell’s ongoing pivotal Phase 3 clinical study, evaluating Bria-IMT, plus immune check point inhibitor (CPI) versus physician's choice in advanced metastatic breast cancer (Bria-ABC), currently has 58 active clinical sites across 15 states. For more information, please visit: https://bit.ly/3ZZg8a1

BriaCell reported a median overall survival (OS) of 13.9 months in triple negative breast cancer (TNBC), exceeding Trode...
07/11/2025

BriaCell reported a median overall survival (OS) of 13.9 months in triple negative breast cancer (TNBC), exceeding Trodelvy (11.8 months) and doubling the control (6.9 months). BriaCell also reported a median overall survival (OS) of 17.3 months in HR+ metastatic breast cancer, surpassing both Trodelvy (14.4 months) and the control group (11.2 months). https://bit.ly/44q98pd

07/11/2025

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) announced updated Phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune check point inhibitor (CPI). For more information, visit: https://bit.ly/44q98pd

BriaCell is pleased to report the sustained complete resolution of temporal lobe brain metastasis and continued orbital ...
07/10/2025

BriaCell is pleased to report the sustained complete resolution of temporal lobe brain metastasis and continued orbital (behind the eye) tumor reduction in the Phase 2 study in MBC. https://bit.ly/4ljhhBA

Address

Philadelphia, PA

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Share

BriaCell Therapeutics

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell based product candidate derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.